Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Lfb Biotechnologies
InventorsAbdessatar Sami Chtourou, Sébastien Lacroix-Desmazes, Srinivas Kaveri, Suryasarathi Dasgupta, Jagaadeesh Bayry
Life of this patent
Estimating the term…
Abstract
There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.
Claims16
A FVIII protein with a procoagulant activity comprising a modified FVIII peptide, wherein the modification of said modified FVIII polypeptide comprises
- the substitution or the deletion of at least one amino acid selected from the group consisting of asparagine 239, and asparagine 2118 with reference to the full length human FVIII polypeptide sequence set forth in SEQ ID NO. 2, and
- at least the first 226 amino acids of the B domain of said full length human FVIII polypeptide sequence.
Dependencies are inferred from the claim text.